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DLC1 encodes a RhoA GTPase-activating protein and tumor suppres-
sor lost in cancer by genomic deletion or epigenetic silencing and
loss of DLC1 gene transcription. We unexpectedly identified non-
small cell lung cancer (NSCLC) cell lines and tumor tissue that
expressed DLC1 mRNA yet lacked DLC1 protein expression. We de-
termined that DLC1 was ubiquitinated and degraded by cullin 4A–
RING ubiquitin ligase (CRL4A) complex interaction with DDB1 and
the FBXW5 substrate receptor. siRNA-mediated suppression of cullin
4A, DDB1, or FBXW5 expression restored DLC1 protein expression in
NSCLC cell lines. FBXW5 suppression-induced DLC1 reexpression
was associated with a reduction in the levels of activated RhoA-
GTP and in RhoA effector signaling. Finally, FBXW5 suppression
caused a DLC1-dependent decrease in NSCLC anchorage-dependent
and -independent proliferation. In summary,we identify a posttrans-
lational mechanism for loss of DLC1 and a linkage between CRL4A-
FBXW5–associated oncogenesis and regulation of RhoA signaling.
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Rho family small GTPases function as extracellular signal-regulated on-off switches that cycle between an active GTP-
bound state and an inactive GDP-bound state. Of the 20 human
Rho family GTPases, the best studied are RhoA, Rac1, and
Cdc42 (1). Rho-selective guanine nucleotide exchange factors
(RhoGEFs) promote GDP-GTP exchange and formation of ac-
tive Rho-GTP, whereas Rho-selective GTPase-activating proteins
(RhoGAPs) stimulate hydrolysis of the bound GTP to return the
GTPase to its inactive Rho-GDP form (2, 3). Rho-GTP binds
preferentially to its downstream effectors, stimulating a diversity
of cytoplasmic signaling cascades that control actin organization,
cell morphology and polarity, cell cycle progression and cell
proliferation, cell survival and migration, and gene expression (4).
In light of their key role in regulating fundamental processes in
cell behavior, it is not surprising that the aberrant activation of
Rho family small GTPases contributes to cancer and other hu-
man disorders (5–8). However, in contrast to the Ras small
GTPase, where direct mutational activation leads to insensitivity
to inactivation by Ras-selective GTPase-activating proteins
(RasGAPs), Rho GTPases are more commonly activated through
indirect mechanisms (2, 3). In human cancers, persistent RhoGEF
activation or loss of RhoGAP stimulation are common mechanisms
leading to aberrant Rho activation. For example, we determined
that the P-Rex1 RhoGEF was up-regulated transcriptionally in
melanoma through persistent activation of the ERK mitogen-acti-
vated protein kinase pathway and the related P-Rex2 isoform was
found mutationally activated in melanoma (9, 10).
With regard toRhoGAPs, one of themost frequent and common
mechanisms involves loss of expression of Deleted in Liver Cancer
1 (DLC1) in liver, breast, lung, ovarian, kidney, colon, stomach,
prostate, and other cancers (3, 11, 12). DLC1 encodes a GAP pri-
marily for RhoA and related isoforms. Initially discovered as a gene
lost in liver cancer by genomic deletion (13), subsequent studies
found that the frequency of DLC1 genomic deletion was compa-
rable to the frequency seen with theTP53 tumor suppressor gene in
lung, colon, breast, and other cancers (14). Other studies also
identified loss of DLC1 mRNA expression through promoter
methylation rather than genomic deletion in a wide variety of hu-
man cancers (15–21). For example, loss of the DLC1 mRNA ex-
pression was found in primary non-small cell lung cancer
(NSCLC) tumors and cell lines, due to aberrant DNA methyla-
tion rather than genomic deletion (20). Ectopic reexpression of
DLC1 impaired growth, supporting a tumor suppressor role in
lung cancer (20, 22).
In our evaluation of DLC1 function in NSCLC, we identified
a subset of NSCLC patient tumors and cell lines that retained
DLC1 mRNA but surprisingly not protein expression, prompting
our speculation that DLC1 loss in cancer may also occur post-
translationally. We determined that DLC1 protein loss was
mediated by ubiquitination and proteasome degradation. We
then searched for the E3 ligase involved and we identified and
established a role for a cullin 4A–RING ubiquitin ligase (CRL4A)
complex interaction with the FBXW5 substrate receptor in
DLC1 protein loss. Suppression of FBXW5 expression restored
DLC1 protein expression, resulting in suppression of RhoA ac-
tivity and effector signaling, causing DLC1-dependent impair-
ment in NSCLC growth. Our studies establish a posttranslational
mechanism of DLC1 loss important for NSCLC biology and define
a link between CRL4 and regulation of Rho GTPase signaling.
Significance
The DLC1 tumor suppressor gene is commonly lost in cancer by
genomic deletion or epigenetic silencing, leading to loss of gene
transcription. DLC1 encodes a GTPase-activating protein for the
RhoA small GTPase, and DLC1 loss of expression results in ab-
errant RhoA activation and signaling. Unexpectedly, we found
that a subset of non-small cell lung cancer patient tumors and
cell lines retained DLC1 mRNA but not protein expression. We
determined that the CUL4A–DDB1–FBXW5 E3 ubiquitin ligase
complex is responsible for loss of DLC1 protein expression.
Suppression of FBXW5 function restored DLC1-dependent lung
cancer cell growth suppression. Our observations identify
a mechanism for posttranslational loss of DLC1 function in
cancer and substrate for CRL4A-FBXW5–driven cancer growth.
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Results
DLC1 Protein Is Lost in DLC1 mRNA-Positive NSCLC Cell Lines and
Tumor Tissue. A previous study found loss of DLC1 transcrip-
tion in lung tumors, but no analyses of DLC1 protein expression
or association with lung subtype, oncogene mutation, or clinical
parameters was determined (20). To address these issues, we
first used Oncomine (www.oncomine.org) analyses of available
datasets that revealed a reduction in DLC1 mRNA expression in
lung tumors compared with normal lung in the majority of
datasets, for example, with a reduction seen in all lung cancer
types from gene expression analysis of 186 human lung carci-
nomas (23) (Fig. S1). We next evaluated DLC1 expression by
immunohistochemistry (IHC) staining of a lung tumor tissue
microarray using a DLC1 antibody that we validated for IHC
detection of DLC1 protein expression (Fig. S2). We found 65%
of lung adenocarcinomas (n = 106) and 79% of squamous cell
lung carcinomas (n = 91) with lost or reduced DLC1 expression
(Fig. 1A). Finally, no significant correlation between DLC1
protein loss and patient survival, or mutant KRAS or EGFR
mutation status, was observed (Table S1).
We previously determined that DLC1 protein was lost in six of
nine NSCLC cell lines (22). To assess the basis for loss of DLC1
protein expression, we used RT-PCR analysis to determine
whether loss of DLC1 mRNA expression correlated with loss
of protein expression. Unexpectedly, we discovered that three
NSCLC cell lines (A549, H23, and SW900) that lacked detectable
DLC1 protein nevertheless expressed DLC1 transcripts (Fig. 1 B
and C). To determine whether this situation was present in pri-
mary patient tumors, nine tumors that were negative by IHC
were evaluated by real-time quantitative reverse transcription–
PCR (qRT-PCR). Two patient tumors showed DLC1 transcript
levels comparable to or higher than a tumor that expressed high
DLC1 protein (Fig. 1D). Thus, a similar frequency of protein-
negative, transcript-positive NSCLC cell lines (3 of 10) and
tumors (2 of 9) was seen.
We therefore speculated that the undetectable DLC1 ex-
pression in these cells may occur by proteasome-mediated pro-
tein degradation. Consistent with this possibility, we found that
treatment with the MG132 proteasome inhibitor resulted in
DLC1 accumulation in all three cell lines (Fig. 1E, Upper) and
increased DLC1 level in a dose-dependent manner in SW900
cells (Fig. 1E, Lower). Because proteasomal protein degradation
is mediated by covalently conjugating polyubiquitin chains to
target proteins, we next investigated whether DLC1 is poly-
ubiquitinated. Using an in vivo ubiquitination assay, where HA-
tagged DLC1 and FLAG-tagged ubiquitin were ectopically
coexpressed, we observed that DLC1 was polyubiquitinated
upon MG132 treatment (Fig. 1F). Together, these results show
that ubiquitin-mediated protein degradation contributes to the
loss of DLC1 expression in multiple NSCLC cell lines.
CUL4A and DDB1 Complex with DLC1 and Regulate DLC1 Protein
Stability. The cullin–RING ligases (CRLs) constitute the largest
E3 ligase family and they target a wide array of substrates for
Fig. 1. DLC1 protein is lost in DLC1 mRNA-positive NSCLC cell lines and tumor tissue, which is mediated by the ubiquitin–proteasome pathway. (A) Immu-
nohistochemical staining analyses of a lung tumor tissue microarray. Shown are representative DLC1 staining of normal and lung tumor tissue. The summary of
IHC scoring distribution of 106 lung adenocarcinomas and 91 squamous cell lung carcinomas is shown. The scoring as determined by a board-certified pa-
thologist for DLC1 comprised staining intensity and extensiveness with the following: 0, negative; 1, weak; 2, moderate; 3, strong. (B) DLC1 expression was
determined in 10 NSCLC cell lines by immunoblot analysis with anti-DLC1 antibody. Blot analysis for β-actin was done to verify equivalent total protein loading.
(C) RT-PCR analysis of DLC1 mRNA expression in the NSCLC cell lines. Analysis of β-actin mRNA expression was done to verify equivalent efficiency of cDNA
synthesis. (D) qRT-PCR analyses of DLC1 mRNA expression in NSCLC patient tumors. Nine NSCLC tumors that were scored as negative (0) by IHC analysis were
evaluated for DLC1 mRNA expression. One NSCLC tumor with strong staining (3) was used as a control for the mRNA level for tumors with high DLC1 protein
expression. Analysis of β-actin mRNA expression was used as an endogenous control. (E) DLC1-negative/DLC1 mRNA-positive NSCLC cells (A549, H23, and
SW900) were treated with vehicle (DMSO) or 10 μM MG132 for 12 h, and SW900 cells were treated with indicated concentration of MG132 for 12 h. Total cell
lysates were subjected to immunoblot analysis with anti-DLC1 and anti–α-tubulin antibodies. (F) HA-tagged DLC1 and FLAG-tagged ubiquitin were coexpressed
in HEK293 cells, followed by treatment with either DMSO or 10 μM MG132 for 6 h. DLC1 was immunoprecipitated with anti-HA antibody and immunoblot
analysis was done with anti-FLAG antibody to detect addition of FLAG-ubiquitin to DLC1. DLC1 expression from total cell lysates was detected with anti-HA
antibody (Lower).








degradation (24–26). The seven cullin proteins (CUL1, 2, 3, 4A,
4B, 5, and 7) can associate with a different family of substrate
receptors, potentially forming as many as 300–500 distinct CRLs.
To determine whether cullin proteins may mediate DLC1 deg-
radation, we carried out coimmunoprecipitation analysis with
a panel of FLAG-tagged dominant-negative forms of each cullin
protein that retain sequences for interaction with their substrates
but not with Rbx-1 and E2 conjugating protein. We found that
GFP- or HA-tagged DLC1 coimmunoprecipitated strongly with
CUL4A, and to a lesser degree, with CUL1 (Fig. 2A and Fig.
S3A). This result suggested that CUL4A-containing CRLs are
the main E3 ubiquitin ligases for DLC1 degradation. In-
terestingly, DLC1 failed to bind to CUL4B, a highly related
paralog of CUL4A (83% amino acid sequence identity). In most
of cases, both CUL4A and CUL4B target the same substrates,
but some target proteins are specific to CUL4A (p27kip1 and
p53) (27) or CUL4B (WDR5) (28). A different subcellular lo-
calization may determine CUL4 paralog substrate specificity.
Whereas CUL4B is predominantly nuclear localized, CUL4A is
cytoplasmic, and may therefore target the cytoplasmic and focal
adhesion-associated DLC1 (29).
CUL4 associates with DDB1, a linker protein that recruits
DDB1-binding and WD40 repeat (DWD box; also known as
DCAF or CDW) proteins (∼90 human members) to form a func-
tional E3 ubiquitin ligase complex (30). To examine whether DLC1
binds CUL4A–DDB1 complex, we first carried out coimmuno-
precipitation analyses with DLC1 and full-length or N-terminal
truncation mutants (ΔN52 or ΔN100) of CUL4A that lack the
DDB1 binding domain (31). DLC1 coimmunoprecipitated with full
length but not with N-terminal truncated CUL4A (Fig. 2B), sug-
gesting a requirement for DDB1 in the DLC1 interaction with
CUL4A. We further observed the interaction between DLC1 and
DDB1 by demonstrating that ectopically expressed DDB1 coim-
munoprecipitated with ectopically expressed DLC1 (Fig. 2C and
Fig. S3B). We also demonstrated that endogenous DLC1 was as-
sociated with immunoprecipitated endogenous DDB1 in NSCLC
cells (Fig. 2D). To address the possibility that the CUL4A–DDB1
complex regulates DLC1 degradation, we examined DLC1 levels
after siRNA suppression of endogenous CUL4A, CUL4B, or
DDB1. Depletion of either CUL4A or DDB1 but not CUL4B
markedly increased DLC1 levels in NSCLC cells (Fig. 2E). These
data indicate that the CUL4A–DDB1 E3 ligase can complex
with and promote DLC1 degradation.
FBXW5 Promotes DLC1 Protein Degradation. To identify the DWD
protein substrate receptor involved in DLC1 degradation, we
evaluated five well-characterized DWD proteins: CDT2, CSA,
DDB2, FBXW5, and VprBP. Transient overexpression of FBXW5
but not the other DWD proteins substantially decreased the
levels of coexpressed DLC1 (Fig. 3A). Consistent with this result,
DLC1 coprecipitated only with FBXW5 (Fig. 3B). We further
demonstrated the interaction between ectopically expressed
FBXW5 with endogenous DLC1 (Fig. 3C) and between endog-
enous FBXW5 and DLC1 (Fig. 3D), suggesting that FBXW5
is a substrate receptor for CUL4A-DDB1–mediated DLC1
degradation.
Human FBXW5 is composed of two recognized domains: an
N-terminal F-box motif and seven WD40 repeats. To determine
the FBXW5 domains required for interaction with DLC1,
FBXW5 deletion mutants (ΔF and ΔWD with deletion of the
F-box motif and WD40 domain, respectively) were used for
a coimmunoprecipitation assay. Full length or ΔF but not ΔWD
coimmunoprecipitated with DLC1, suggesting that FBXW5
binds to DLC1 via the WD40 repeats (Fig. 3E). To evaluate
whether FBXW5 regulates DLC1 degradation, we evaluated
four lentiviral shRNA constructs expressing short hairpin RNA
(shRNA) targeting FBXW5 and identified one shRNA with
effective knockdown of FBXW5 (Fig. S4). After FBXW5 depletion,
we determined that DLC1 polyubiquitination was decreased sig-
nificantly (Fig. 3F) and the level of endogenous DLC1 was greatly
increased inH1299 cells (Fig. 3G,Left). Knockdown of FBXW5by
using two nonoverlapping siRNAs also led to an increase in DLC1
level (Fig. S5A), suggesting that FBXW5 facilitates CUL4A–
DDB1 degradation of DLC1. Furthermore, we observed that
siRNA-mediated knockdown of FBXW5 increases the half-life of
DLC1 (Fig. S5B). Next, we explored the possibility whether
FBXW5 is responsible for the diminished levels of DLC1 protein
inDLC1mRNA-positive cells (Fig. 1 B andC), and we found that
silencing FBXW5 was associated with elevated DLC1 expression
in all three NSCLC cell lines (Fig. 3G, Right). FBXW5 appears to
be the predominant E3 ligase for DLC1 in H23 cells, because the
level of DLC1 in FBXW5-depleted cells was not further increased
by the additional treatment with MG132 (Fig. 3H). These data
demonstrate that FBXW5 is the receptor protein associated
with CUL4A–DDB1 to promote DLC1 degradation in DLC1
protein-deficient, DLC1 mRNA-positive NSCLC cells. Finally,
because protein level and stability of DLC1 was increased in
DLC1 protein-positive cells by suppression of FBXW5 expres-
sion, in some NSCLC cells both transcriptional and post-
translational mechanisms of regulation determine the steady-
state levels of DLC1.
Fig. 2. CUL4A–DDB1 complex interacts with DLC1 and regulates DLC1 sta-
bility. (A) HEK293 cells were cotransfected with plasmids expressing GFP-tagged
DLC1 and FLAG-tagged truncation mutants of the indicated cullin proteins for
24 h, followed by treatment with 10 μM MG132 for 4 h. Cell lysates and anti-
FLAG immunoprecipitates were subject to immunoblot analysis with the in-
dicated antibodies to determine FLAG-CUL proteins, which interact with DLC1.
(B and C) HEK293 cells were cotransfected with plasmids expressing GFP-tagged
DLC1 andMyc-tagged full-length or N-terminal truncated mutants of CUL4A (B)
or with plasmids expressing GFP-tagged DLC1 and T7 epitope-tagged DDB1 (C)
for 24 h, followed by treatment of 10 μMMG132 for an additional 4 h. Total cell
lysates and anti-Myc (B) or -GFP (C) immunoprecipitates were subjected to
immunoblot analysis with the indicated antibodies to determine the residues in
CUL4A for DLC1 binding (B) or DLC1 interacts with DDB1 (C). (D) H23 and H1299
cells were treated with 10 μM MG132 for 6 h. Immunoprecipitates with normal
IgG or DLC1 antibodies were subjected to immunoblot analysis with the in-
dicated antibodies to detect an endogenous DLC1 and DDB1 association. (E)
H1299 and H1703 cells were transfected with siRNAs targeting the indicated
genes for 2 d. Immunoblot analysis was done with anti-DLC1 antibody to de-
termine DLC1 level, with anti-CUL4A, CUL4B, or DDB1 antibodies to examine
the knockdown of each protein, or with anti–α-tubulin to verify equivalent total
protein loading.
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FBXW5 Depletion-Mediated Restoration of DLC1 Inhibits Rho GTPase
Signaling and NSCLC Cell Proliferation. Because DLC1 functions as
a RhoGAP activity, we reasoned that DLC1 accumulation in
FBXW5-depleted cells might cause a reduction in RhoA acti-
vation and signaling. To this end, we examined the effects of
DLC1 restoration on RhoA downstream effector signaling. The
ROCK serine/threonine kinases are key effectors of RhoA-
dependent growth transformation (32) and DLC1 has been
shown to be a negative regulator of ROCK activation and sig-
naling (33). RhoA activation of ROCK leads to phosphorylation
of cofilin. Stable FBXW5 knockdown in H23 cells was associated
with greatly reduced levels of phosphorylated cofilin (Fig. 4A).
To investigate whether the reduced cofillin phosphorylation was
mediated by DLC1 RhoGAP activity, we overexpressed wild-
type or GAP-dead mutant (R718E) of DLC1 in H23 cells and
measured RhoA-GTP levels by Rho-binding domain (RBD) pull-
down assay and cofilin phosphorylation level. Overexpression of
wild-type but not GAP-dead DLC1 reduced RhoA-GTP levels
and cofilin phosphorylation level (Fig. 4B).
Because DLC1 can function as a tumor suppressor in NSCLC,
we next determine whether the DLC1 restoration caused by FBXW5
depletion might have effects on NSCLC cell growth. We observed
that stable knockdown of FBXW5 and the subsequent increase
in DLC1 in H23 cells was associated with a significant impair-
ment in cell proliferation (Fig. 4 C and D). FBXW5 has also
been shown to act as a substrate receptor for the SCF (SKP–
Cullin–F box) ubiquitin ligase complex, targeting HsSAS-6 or
Eps8 for ubiquitination and degradation, to regulate centrosome
duplication or mitotic progression, respectively (34, 35). Thus,
FBXW5 may have functions independent of DLC1 in NSCLC.
However, we found that the growth-inhibitory activity seen upon
suppression of FBXW5 was significantly reversed by concurrent
suppression of DLC1 (Fig. 4C). We also observed similar results
for NSCLC cell line anchorage-independent growth in soft agar
(Fig. 4E). Suppression of FBXW5 caused a ∼90% reduction in
soft agar colony formation, whereas concurrent suppression of
DLC1 restored colony formation to ∼90% the level seen with
control nonspecific shRNA treatment. These results suggest that
DLC1 is a significant substrate for FBXW5-dependent NSCLC
tumor cell proliferation. When taken together, these observa-
tions suggest that FBXW5-dependent DLC1 degradation con-
tributes to NSCLC growth.
Fig. 3. FBXW5 binds to DLC1 for promoting its degradation. (A and B) HEK293 cells were cotransfected with plasmids expressing GFP-tagged DLC1 and
indicated Myc-tagged DWD box-containing proteins for 24 h (A) or followed by treatment with 10 μM MG132 for 4 h (B). Cell lysates or anti-Myc immu-
noprecipitates were analyzed by immunoblot analysis with the indicated antibodies to determine a DWD protein that destabilizes DLC1 (A) or a DWD protein
that binds to DLC1 (B). (C) H1299 cells transfected with plasmids expressing Myc-tagged FBXW5 for 24 h were treated with 10 μM MG132 for 4 h. Cell lysates
and anti-Myc immunoprecipitates were subjected to immunoblot analysis with the indicated antibodies to detect a Myc–FBXW5 interaction with endogenous
DLC1. (D) Equal amount of cell lysates from MG132-treated H1299 cells (10 μM, 6 h) were immunoprecipitated with anti-HA or anti-FBXW5 antibodies,
followed by immunoblot analysis with the indicated antibodies to detect an endogenous DLC1 and FBXW5 interaction. (E) HEK293 cells were cotransfected
with plasmids expressing GFP-tagged DLC1 and Myc-tagged full length, F-box (ΔF), or WD40-domain (ΔWD) truncation mutants of FBXW5 for 24 h, followed
by treatment with 10 μM MG132 for 4 h. Cell lysates and anti-GFP immunoprecipitates were subjected to immunoblot analysis with the indicated antibodies
to determine FBXW5 residues responsible for binding to DLC1. (F) HEK293 cells were transfected with HA-tagged DLC1 and FLAG-tagged ubiquitin for 24 h
and infected with lentivirus expressing shRNA targeting FBXW5 or nonspecific shRNA (NS) for 2 d, followed by the treatment with 10 μMMG132 for 6 h. Anti-
HA immunoprecipitates were subjected to immunoblot analysis with anti-FLAG antibody to detect DLC1 polyubiquitination. Cell lysates were analyzed with
anti-FBXW5 and α-tubulin antibodies to determine the knockdown of FBXW5 protein and equivalent protein loading, respectively. (G) NSCLC cells were
infected with lentivirus expressing shRNA targeting FBXW5 or NS shRNA, and selected with puromycin for 2 d, and then subjected to immunoblot analysis
with anti-DLC1 antibody to determine DLC1 level, anti-FBXW5 antibody to examine knockdown of FBXW5, or anti–α-actin antibody to determine equivalent
protein loading. (H) H23 cells which stably expressing NS or FBXW5 shRNA were treated with treated with DMSO or 10 μM MG132 for 6 h. Cell lysates were
analyzed with anti-DLC1 or α-tubulin antibodies to determine DLC1 level and equivalent protein loading, respectively.









The loss of expression of DLC1 comprises one of the most widely
observed mechanisms by which Rho GTPases become aberrantly
activated in cancer (12). Loss of DLC1 gene transcription has
been attributed to genomic deletion at a frequency comparable
with that seen with the TP53 tumor suppressor gene in lung,
colon, breast, and other cancers (14). Epigenetic gene silencing
including promoter methylation has also been described to be
a commonmechanism ofDLC1 gene expression loss in cancer. Our
study describes a ubiquitination–proteasome degradation mecha-
nism through a CUL4A–DDB1–FBXW5 complex that accounts
for the loss of DLC1 protein in a significant subset of NSCLCs. We
also determined that this loss of DLC1 expression contributes to
aberrantRhoA activation and signaling, promotingNSCLC growth.
We previously determined that FBXW5 facilitated CUL4–DDB1
degradation of the Tsc2 tumor suppression. Thus, our studies
identify a second target for this E3 ligase complex, both tumor
suppressors, and additionally establish a link between CRL4 and
regulation of RhoA and the actin cytoskeleton.
A previous study found a significant decrease or absence of
DLC1 mRNA expression was found in 95% of primary NSCLC
(20 of 21) and 58% of NSCLC cell lines (11 of 19) (20). Because
no protein expression analyses were done in patient tumors or
evaluated in specific lung cancer subtypes, we performed IHC
analyses of DLC1 protein expression in a lung tumor tissue
microarray. We found that 65% of lung adenocarcinomas and
79% of squamous cell lung carcinomas exhibited lost or reduced
DLC1 expression, indicating that DLC1 protein expression is
reduced in a majority of NSCLC. Compared with the frequency
of alterations in other genes in NSCLC (e.g., TP53, 26%; EGFR,
23%; KRAS, 16%; CDKN2A, 15% mutation) (COSMIC), DLC1
loss represents one of the most frequent genetic alterations
found in this cancer.
A previous study showed that DLC1 protein is regulated by
the 26S proteasome in a human liver cancer cell line (36), but no
mechanism for DLC1 protein degradation nor biological con-
sequences was elucidated. Here, we show that the CUL4A–
DDB1–FBXW5 complex regulates DLC1 degradation in NSCLCs.
We previously identified FBXW5 as the receptor protein for
CUL4A/B-DDB1–dependent degradation of the Tsc2/tuberin
tumor suppressor (37), a GAP for the Rheb small GTPase.
To date, ∼30 substrate proteins are known to be targeted by
CRL4 complexes and most substrates are associated with chro-
matin formation, DNA replication, and DNA damage repair
(24). Only two substrates have been reported to be related to
cancer, as demonstrated by the degradation of Merlin and TSC2
tumor suppressor by VprBP (38) and FBXW5 (37), respectively.
Therefore, we here add another tumor suppressor, DLC1, which
is regulated by CRL4 complexes, implicating that CRL4 has
cancer-related roles in addition to DNA-related functions.
In addition to CUL4–DDB1, FBXW5 has also been shown to
act as a substrate receptor for the CUL1–SKP1 E3 ubiquitin li-
gase complex, targeting HsSAS-6 or Eps8 for ubiquitination and
degradation, to regulate centrosome duplication or mitotic
progression, respectively (34, 35). In contrast, FBXW5 through
CUL4–DDB1 promotes sumoylation rather than ubiquitination
of the Myb transcription factor, to alter its nuclear localization
and transcriptional activity (39). Thus, FBXW5 may have func-
tions independent of DLC1 in NSCLC. However, because we
found that the growth-inhibitory activity seen upon suppression
of FBXW5 were significantly reversed by concurrent suppression
of DLC1, in NSCLC cells, a predominant function of FBXW5 is
the targeted degradation of DLC1.
Interestingly, we did not observe increased TSC2 protein when
FBXW5 was depleted in NSCLC cell lines, suggesting context-
dependent roles for FBXW5. The stability of another RhoGAP
protein, p190RhoGAP, was not changed by FBXW5 depletion,
indicating the substrate specificity of FBXW5 (Fig. S5C). The
molecular mechanisms that regulate DLC1 protein stability
among NSCLC cell lines are not clear at present. It was reported
that the Polo-like kinase 4 (PLK4) inactivates FBXW5 by phos-
phorylation on Ser151 residue (34) and PLK4 is down-regulated in
cancer (40). Therefore, an abnormal activation of FBXW5 by
PLK4 down-regulation could be a possible mechanism for a more
rigorous degradation of DLC1 protein in DLC1 protein-negative
NSCLCs. However, we did not observe any significant difference
in PLK4 protein levels in DLC1 mRNA/protein-positive cells and
DLC1 mRNA positive/protein-negative cells (Fig. S6). We also
compared the protein level of each component of the E3 ubiquitin
ligase complex to determine whether their expression correlatedwith
loss of DLC1 protein. We did not detect any notable differences in
CUL4A and DDB1 protein levels between two groups, and fur-
thermore, the level of FBXW5 was less in DLC1 mRNA-positive/
protein-negative cell lines (Fig. S6). These results suggest that the
modification of DLC1 rather than differential expression of CRL4A
Fig. 4. FBXW5 depletion-associated DLC1 increase inhibits RhoA activa-
tion and signaling and NSCLC cell proliferation. (A) Cell lysates from H23
cells stably expressing NS or FBXW5 shRNA were subjected to immunoblot
analysis with the indicated antibodies to determine whether DLC1 stabi-
lization caused by FBXW5 suppression is associated with a decrease in the
level of phosphorylated cofilin. (B) Cell lysates from H23 cells stably expressing
HA-tagged wild-type DLC1 (WT) or mutant DLC1 (R718E; GAP-dead) were
assessed by pull-down analysis with GST–Rhotekin–RBD. Precipitated and total
cell lysates were immunoblotted with anti-RhoA antibody to detect RhoA-GTP
and total RhoA, respectively. Cell lysates from the stable cell lines were ana-
lyzed with anti-total or –phospho-cofilin (serine 3) to determine whether
cofilin phosphorylation level is associated with DLC1 RhoGAP activity, or with
anti-HA antibody to determine DLC1 expression. (C) H23 cells stably expressing
shRNA for GFP or DLC1 were further infected with NS or FBXW5 shRNA len-
tiviral particles and selected with puromycin. Cell proliferation was monitored
by quantitation of cell number every 3 d. Data shown are the average of
triplicate wells for each time point. (D) Cell lysates from the H23 stable cells in
C were analyzed with anti-DLC1 antibody to monitor DLC1 protein levels and
anti–α-tubulin antibody to verify equivalent protein. (E) Colony formation of
the H23 stable cells in soft agar was monitored and quantitated. Colony for-
mation was then normalized to NS shRNA (1.00), relative to colony formation
seen with shRNA silencing of FBXW5 (0.09) or combination silencing of FBXW5
together with DLC1 (0.87).
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components is likely the basis for DLC1 ubiquitination–degradation
inNSCLC. TheDLC1 functional residues reported thus far were not
related with DLC1 stability (Fig. S7). An important future direction
will be the identification of DLC1 residue(s) critical for regulating
DLC1 stability. Because binding to F-box proteins commonly re-
quires phosphorylation of the substrate, DLC1 phosphorylation will
be a key determinant for stimulating DLC1 degradation. Hence,
pharmacologic approaches that modulate protein kinase function
to preventDLC1 degradationmay be a viable therapeutic approach
to restore DLC1 tumor suppressor function in lung cancer.
In summary, we identified a mechanism in which DLC1 tumor
suppressor function is lost by protein degradation by the CRL4A–
FBXW5 ubiquitin ligase complex.We also demonstrated that DLC1
restoration is partially responsible for the FBXW5 knockdown-
mediated suppression of NSCLC cell growth and suggested that
RhoA signaling through RhoA–ROCK–cofilin pathway via
RhoGAP activity of DLC1 might be a cellular mechanism for
DLC1 restoration effects onNSCLC cell growth.Our studies identify
a target for CRL4A–FBXW5 that provides a link with Rho GTPase
regulation. With substantial evidence for Rho GTPases in cancer
(41), our identification of DLC1 as a substrate for CRL4A–FBXW5
further diversifies the cellular processes that when deregulated can
facilitate Rho GTPase-driven cancer cell growth.
Materials and Methods
Immunohistochemical evaluation of DLC1 protein expression was performed
on a lung tumor tissue microarray as described previously (42). Specimen blocks
chosen for the tissue microarray met the criteria of nonnecrotic, nonirradiated,
or chemo-treated lung cancer tissue. NSCLC subtypes included adenocarci-
noma (n = 106) and squamous cell carcinoma (n = 91). Tumor tissue staining for
DLC1 was performed on a BondMax autostainer (Leica Microsystems) using a
purified mouse monoclonal antibody from BD Biosciences. Full methods for
cell culture, immunohistochemistry, constructs, siRNA and transfection, immu-
noblotting and immunoprecipitation, qRT-PCR, cell proliferation and colony
formation, in vivo ubiquitination assays, and RhoA activation assay are avail-
able in SI Materials and Methods.
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